在LGMN mRNA上依赖METTL3的N6-甲基氨酸修饰促进了巨细胞铁和动脉样硬化
Yang He1, Kaisheng Jiang1, Junhong Sun2
1Faculty of Forensic Medicine, Guangdong Province Translational Forensic Medicine Engineering Technology Research Center, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.
Journal of molecular and cellular cardiology
|January 8, 2026
概括
N6-甲基氨酸 (m6A) 修饰和甲基转移酶样3 (METTL3) 通过诱导巨细胞通过豆类蛋白 (LGMN) 进行铁亡,从而促进动脉样硬化. 抑制METTL3或LGMN可以减少巨细胞中的斑块形成和铁亡.
科学领域:
- 生物化学和分子生物学
- 免疫学 免疫学 免疫学
- 心血管研究研究心血管研究
背景情况:
- N6-甲基氨酸 (m6A) 修饰在生物过程中至关重要,但其在巨细胞和动脉样硬化 (AS) 铁亡中的作用尚不清楚.
- 在AS动脉中发现升高的m6A修饰和甲基转移酶样3 (METTL3),在小鼠和人类AS中增加METTL3阳性巨细胞.
- 巨细胞功能和铁亡与AS病变发生有关.
研究的目的:
- 调查m6A修饰和METTL3在动脉样硬化期间巨驱动铁亡中的作用.
- 为了确定AS病原体中METTL3的下游目标.
- 阐明AS中METTL3,铁和豆类蛋白 (LGMN) 之间的联系机制.
主要方法:
- 在AS的小鼠模型中,系统性和巨细胞特定的METTL3敲击.
- 在METTL3敲除后,骨髓衍生的巨细胞 (BMDM) 的RNA测序.
- 在BMDM和AS小鼠模型中,对氧化低密度脂蛋白 (ox-LDL) 和METTL3/LGMN操纵的反应中,对豆类蛋白 (LGMN) 表达的分析.
- 调查YTHDF1与m6A修饰的LGMNmRNA结合的情况.
主要成果:
- 抑制或淘汰METTL3可以减少AS斑块的形成和巨细胞的透.
- 在BMDM中METTL3敲除丰富了与铁相关的基因.
- 在AS动脉和ox-LDL治疗的BMDM中,LGMN表达被上调;在体外和体内,LGMN knockdown减弱了ox-LDL诱导的铁,脂质沉积和炎症.
- 抑制METTL3抑制了LGMN上调,而LGMN过度表达挽救了METTL3的淘汰效应.
- YTHDF1调解了m6A修饰的LGMN mRNA的翻译.
结论:
- LGMN作为一种新型调解剂,将METTL3依赖的m6A修饰与动脉样硬化中的巨细胞铁死联系起来.
- 在巨细胞中准METTL3-LGMN轴可能为AS提供治疗策略.
- 在AS的背景下,m6A修饰在调节巨细胞功能和铁化方面发挥着重要作用.
相关概念视频
Formation of Muscle Fibers from Myoblasts
De novo myogenesis, or the formation of muscle fibers, begins during the early embryonic stages. The skeletal muscle is formed from somites– blocks of embryonic cell layers. The somites are further divided into dermatomes, myotomes, sclerotomes, and syndetomes. Among these, the myotomes give rise to muscle fibers.
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription factors...
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription factors...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
